Every Form 4 that abrdn Life Sciences Investors (HQL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HQL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HQL filings page.
abrdn Life Sciences Investors director Chris LaVictoire Mahai purchased 527 shares of Common Stock on 2026-07-16 in an open-market or private transaction at $19.92 per share. After this trade, Mahai directly owns 527 shares of HQL. The filing indicates the transaction was not under a Rule 10b5-1 trading plan.
abrdn Life Sciences Investors reported that one of its directors acquired 7,923 shares of its common stock on 12/16/2025 at a price of $16.8818 per share. Following this transaction, the director directly beneficially owned 7,923 shares of the company.
Saba Capital Management, L.P. reported insider sales of abrdn Life Sciences Investors (HQL) common stock on a Form 4. The filing lists two dispositions: 6,989 shares sold on 09/19/2025 at $14.10 and 41,623 shares sold on 09/22/2025 at $14.14. After the reported transactions, Saba Capital’s beneficial ownership is shown as 2,837,633 shares (indirect), down from 2,879,256 shares following the earlier sale. The Form identifies the reporting entity as Saba Capital Management, L.P., with signatures dated 09/23/2025.